Concepts (92)
Concepts are derived automatically from a person's publications.
Concepts are listed by decreasing relevance which is based on many factors, including how many publications the person wrote about that topic, how long ago those publications were written, and how many publications other people have written on that same topic.
| Name |
Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Stroke | 7 | 2022 | 240 | 1.480 |
Why?
|
| Fibrinolytic Agents | 6 | 2022 | 56 | 0.970 |
Why?
|
| Tissue Plasminogen Activator | 5 | 2016 | 39 | 0.730 |
Why?
|
| Subarachnoid Hemorrhage | 5 | 2019 | 39 | 0.590 |
Why?
|
| Remote Consultation | 1 | 2016 | 9 | 0.500 |
Why?
|
| Cerebral Hemorrhage | 3 | 2020 | 104 | 0.360 |
Why?
|
| Hospital Mortality | 3 | 2016 | 133 | 0.330 |
Why?
|
| Infarction, Middle Cerebral Artery | 4 | 2014 | 10 | 0.320 |
Why?
|
| Thrombolytic Therapy | 4 | 2016 | 42 | 0.320 |
Why?
|
| Middle Aged | 12 | 2022 | 8055 | 0.260 |
Why?
|
| Posterior Leukoencephalopathy Syndrome | 2 | 2019 | 9 | 0.260 |
Why?
|
| Vasospasm, Intracranial | 2 | 2019 | 9 | 0.250 |
Why?
|
| Aged | 11 | 2022 | 7552 | 0.250 |
Why?
|
| Thrombectomy | 2 | 2017 | 30 | 0.240 |
Why?
|
| Retrospective Studies | 7 | 2022 | 3040 | 0.220 |
Why?
|
| Humans | 19 | 2022 | 23331 | 0.210 |
Why?
|
| Severity of Illness Index | 3 | 2016 | 813 | 0.210 |
Why?
|
| Pandemics | 2 | 2022 | 203 | 0.200 |
Why?
|
| Time Factors | 5 | 2020 | 1289 | 0.200 |
Why?
|
| beta-Alanine | 2 | 2012 | 3 | 0.190 |
Why?
|
| Benzimidazoles | 2 | 2012 | 9 | 0.190 |
Why?
|
| Female | 14 | 2021 | 13124 | 0.180 |
Why?
|
| Anticoagulants | 2 | 2012 | 85 | 0.180 |
Why?
|
| Systemic Inflammatory Response Syndrome | 1 | 2021 | 21 | 0.180 |
Why?
|
| Magnetic Resonance Imaging | 2 | 2016 | 880 | 0.170 |
Why?
|
| Male | 13 | 2020 | 12629 | 0.170 |
Why?
|
| Atrial Fibrillation | 2 | 2012 | 98 | 0.170 |
Why?
|
| Tertiary Care Centers | 1 | 2020 | 66 | 0.160 |
Why?
|
| Intracranial Thrombosis | 1 | 2019 | 6 | 0.160 |
Why?
|
| Endocarditis | 1 | 2019 | 10 | 0.160 |
Why?
|
| Brain Ischemia | 1 | 2020 | 61 | 0.160 |
Why?
|
| Nervous System Diseases | 1 | 2020 | 99 | 0.150 |
Why?
|
| Coronavirus Infections | 1 | 2020 | 79 | 0.150 |
Why?
|
| Pneumonia, Viral | 1 | 2020 | 83 | 0.150 |
Why?
|
| Acute Disease | 2 | 2016 | 168 | 0.150 |
Why?
|
| Cerebral Amyloid Angiopathy | 1 | 2019 | 94 | 0.140 |
Why?
|
| International Normalized Ratio | 2 | 2014 | 18 | 0.130 |
Why?
|
| Arterial Occlusive Diseases | 1 | 2017 | 8 | 0.130 |
Why?
|
| Patient Transfer | 1 | 2017 | 25 | 0.130 |
Why?
|
| Aged, 80 and over | 7 | 2019 | 3783 | 0.130 |
Why?
|
| Cerebral Infarction | 1 | 2016 | 109 | 0.120 |
Why?
|
| Socioeconomic Factors | 1 | 2016 | 270 | 0.120 |
Why?
|
| Informed Consent | 1 | 2015 | 22 | 0.120 |
Why?
|
| Renal Dialysis | 1 | 2015 | 82 | 0.110 |
Why?
|
| Reperfusion | 1 | 2014 | 7 | 0.110 |
Why?
|
| Kidney Failure, Chronic | 1 | 2015 | 123 | 0.110 |
Why?
|
| Neoplasms | 1 | 2016 | 221 | 0.110 |
Why?
|
| Brain Edema | 1 | 2013 | 18 | 0.100 |
Why?
|
| Encephalocele | 1 | 2013 | 21 | 0.100 |
Why?
|
| Intracranial Hypertension | 1 | 2013 | 12 | 0.100 |
Why?
|
| Predictive Value of Tests | 3 | 2019 | 442 | 0.090 |
Why?
|
| Risk Factors | 4 | 2019 | 1998 | 0.090 |
Why?
|
| Adult | 5 | 2019 | 7070 | 0.070 |
Why?
|
| Diffusion Magnetic Resonance Imaging | 2 | 2020 | 88 | 0.070 |
Why?
|
| Young Adult | 3 | 2019 | 1674 | 0.070 |
Why?
|
| Cerebral Angiography | 2 | 2019 | 29 | 0.060 |
Why?
|
| Treatment Outcome | 3 | 2017 | 2988 | 0.050 |
Why?
|
| Tomography, X-Ray Computed | 2 | 2014 | 593 | 0.040 |
Why?
|
| Vasoconstriction | 1 | 2019 | 14 | 0.040 |
Why?
|
| Computed Tomography Angiography | 1 | 2019 | 27 | 0.040 |
Why?
|
| Syndrome | 1 | 2019 | 70 | 0.040 |
Why?
|
| Betacoronavirus | 1 | 2020 | 68 | 0.040 |
Why?
|
| Recurrence | 1 | 2019 | 272 | 0.040 |
Why?
|
| Comorbidity | 1 | 2020 | 431 | 0.040 |
Why?
|
| Sex Factors | 1 | 2019 | 391 | 0.040 |
Why?
|
| Reproducibility of Results | 1 | 2019 | 594 | 0.030 |
Why?
|
| Age Factors | 1 | 2019 | 641 | 0.030 |
Why?
|
| Chicago | 1 | 2020 | 819 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2017 | 30 | 0.030 |
Why?
|
| Statistics, Nonparametric | 1 | 2016 | 106 | 0.030 |
Why?
|
| Adolescent | 1 | 2021 | 1916 | 0.030 |
Why?
|
| Prospective Studies | 1 | 2020 | 1523 | 0.030 |
Why?
|
| Administration, Intravenous | 1 | 2015 | 23 | 0.030 |
Why?
|
| Ischemic Attack, Transient | 1 | 2015 | 15 | 0.030 |
Why?
|
| Disability Evaluation | 1 | 2016 | 218 | 0.030 |
Why?
|
| Fibrinogen | 1 | 2014 | 22 | 0.030 |
Why?
|
| Blood Coagulation Factors | 1 | 2014 | 19 | 0.030 |
Why?
|
| Early Diagnosis | 1 | 2014 | 52 | 0.030 |
Why?
|
| Magnetic Resonance Angiography | 1 | 2014 | 27 | 0.030 |
Why?
|
| Fatal Outcome | 1 | 2014 | 51 | 0.030 |
Why?
|
| Brain | 1 | 2020 | 1200 | 0.020 |
Why?
|
| Ultrasonography, Doppler, Transcranial | 1 | 2012 | 3 | 0.020 |
Why?
|
| Area Under Curve | 1 | 2012 | 60 | 0.020 |
Why?
|
| Cerebrovascular Circulation | 1 | 2012 | 28 | 0.020 |
Why?
|
| Data Interpretation, Statistical | 1 | 2012 | 60 | 0.020 |
Why?
|
| Partial Thromboplastin Time | 1 | 2012 | 6 | 0.020 |
Why?
|
| Platelet Count | 1 | 2012 | 11 | 0.020 |
Why?
|
| Dabigatran | 1 | 2012 | 6 | 0.020 |
Why?
|
| Blood Coagulation | 1 | 2012 | 21 | 0.020 |
Why?
|
| ROC Curve | 1 | 2012 | 125 | 0.020 |
Why?
|
| Risk Assessment | 1 | 2014 | 565 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2012 | 1429 | 0.020 |
Why?
|